BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 17353651)

  • 1. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
    Aznaouridis KA; Vyssoulis GP; Karpanou EA; Marinakis AG; Barbetseas JD; Zervoudaki AI; Cokkinos DV; Stefanadis CI
    Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
    Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy.
    Gosse P; Roudaut R; Herrero G; Dallocchio M
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S145-50. PubMed ID: 11527119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril.
    Díez J; Laviades C
    J Hypertens Suppl; 1994 Jul; 12(4):S31-6. PubMed ID: 7965272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of cilazapril therapy on diastolic filling and left ventricular hypertrophy in patients with arterial hypertension].
    De Simone R; Irace L; Perna B; Caruso C; Guida M; Iacono A
    Minerva Cardioangiol; 1993 May; 41(5):205-9. PubMed ID: 8355860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan.
    Avanza AC; El Aouar LM; Mill JG
    Arq Bras Cardiol; 2000 Feb; 74(2):103-17. PubMed ID: 10904284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse white-coat effect as an independent risk for left ventricular concentric hypertrophy in patients with treated essential hypertension.
    Tomiyama M; Horio T; Kamide K; Nakamura S; Yoshihara F; Nakata H; Nakahama H; Kawano Y
    J Hum Hypertens; 2007 Mar; 21(3):212-9. PubMed ID: 17167525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor.
    Kohno M; Horio T; Yokokawa K; Yasunari K; Ikeda M; Minami M; Kurihara N; Takeda T
    Am J Med; 1995 Mar; 98(3):257-65. PubMed ID: 7872342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in plasma cardiac natriuretic peptides concentrations during 1 year treatment with angiotensin-converting enzyme inhibitor in elderly hypertensive patients with left ventricular hypertrophy.
    Kohno M; Yokokawa K; Yasunari K; Kano H; Minami M; Hanehira T; Yoshikawa J
    Int J Clin Pharmacol Ther; 1997 Jan; 35(1):38-42. PubMed ID: 9021441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors influence left ventricular mass and function independently of the antihypertensive effect.
    Grandi AM; Laurita E; Solbiati F; Marchesi C; Maresca AM; Nicolini E; Guasti L; Venco A
    J Cardiovasc Pharmacol; 2006 Nov; 48(5):207-11. PubMed ID: 17110802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of angiotensin-converting enzyme gene polymorphism and serum vitamin D levels on ambulatory blood pressure measurement and left ventricular mass in Turkish hypertensive population.
    Kulah E; Dursun A; Aktunc E; Acikgoz S; Aydin M; Can M; Dursun A
    Blood Press Monit; 2007 Aug; 12(4):207-13. PubMed ID: 17625392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [I/D gene polymorphism of the angiotensin-converting enzyme and left ventricular hypertrophy. Response to converting enzyme inhibitors].
    Rugale C; du Cailar G; Ribstein J; Mimran A
    Arch Mal Coeur Vaiss; 2003; 96(7-8):772-5. PubMed ID: 12945221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of diastolic function after regression of left ventricular hypertrophy.
    Teniente-Valente R; Solorio S; Vargas-Salado E; Aguirre-Vázquez C; Hernández-González MA; Olvera-Lopez JA; Rodríguez-Mariscal L; Luna-Ruiz MA; Guillén Contreras JM; Murillo Ortiz BO
    Arch Cardiol Mex; 2008; 78(4):392-9. PubMed ID: 19205547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Association between angiotensin converting enzyme gene, chymase gene and regression of left ventricular hypertrophy in patients treated with angiotensin converting enzyme inhibitors].
    He H; Li LM; Cao WH; Liu MZ; Sun NL; Lü J; Hu YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Sep; 25(9):756-60. PubMed ID: 15555355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different role of wave reflection magnitude and timing on left ventricular mass reduction during antihypertensive treatment.
    Hashimoto J; Westerhof BE; Westerhof N; Imai Y; O'Rourke MF
    J Hypertens; 2008 May; 26(5):1017-24. PubMed ID: 18398345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-four-hour heart rate and blood pressure are additive markers of left ventricular mass in hypertensive subjects.
    Zakopoulos NA; Ikonomidis I; Vemmos KN; Manios E; Spiliopoulou I; Tsivgoulis G; Spengos K; Psaltopoulou D; Mavrikakis M; Moulopoulos SD
    Am J Hypertens; 2006 Feb; 19(2):170-7. PubMed ID: 16448887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.